Four GOP members of the House of Representatives joined with House Democrats to force a vote on extending tax credits that ...

In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals ...

Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...

The drop reflects investors reactions to Pfizer’s new 2026 revenue forecasts, which is set to be between the range of $59.5 billion to $62.5 billion, a decline of $1.5 billion from 2025’s estimated ...

The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

Gabriela P. Baron ([email protected]) is a member of the New York bar and a graduate of New York University School of Law and Vassar College. She is Senior Vice President at Conduent Legal ...

Lunit’s new collaboration with Daiichi Sankyo integrates AI-driven digital pathology tools into oncology translational ...

In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a ...

FDA has announced the approval of LIB Therapeutics’ Lerochol (lerodalcibep-liga) for subcutaneous (SC) use as an adjunct to ...

Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...

Per the terms of the agreement, Sobi is expected to pay upwards of $950 million upfront in cash to acquire Arthrosi.The deal ...